Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive crawled time : 22:00 save search
Giant-Cell Arteritis Market to Showcase Positive Growth at a CAGR of 9.3% by 2034 | DelveInsight
Published: 2024-04-08 (Crawled : 22:00) - prnewswire.com
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: -0.3%
H: 0.0%
C: 0.0%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.05%
H: 0.02%
C: -2.62%
MOR | $18.02 -0.11% -0.11% 590K
|
Health Technology
|
| O: 0.06%
H: 0.22%
C: 0.0%
KNSA | $16.88 -0.41% -0.41% 410K
|
Health Technology
|
| O: 0.23%
H: 1.58%
C: 0.06%
IMAB | $1.795 -0.83% -0.84% 140K
|
Health Technology
|
| O: -0.55%
H: 1.39%
C: 0.0%
GLPG | $28.9 -1.1% -1.11% 140K
|
Health Technology
|
| O: 0.0%
H: 0.39%
C: -0.66%
positive growth market
Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
Published: 2024-04-02 (Crawled : 22:00) - biospace.com/
MIRM | $23.6 -1.05% -1.06% 400K
|
Health Technology
|
| O: -1.3%
H: 0.7%
C: 0.36%
pruritus positive livmarli
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease
Published: 2024-04-01 (Crawled : 22:00) - globenewswire.com
OCGN | News A | $1.315 -8.68% -9.51% 8M
|
Health Technology
|
| O: -10.0%
H: 0.69%
C: -4.17%
ocu410 disease review positive study
Satellos Presents Positive Preclinical Efficacy Data for SAT-3247 at the 2024 MDA Clinical & Scientific Conference
Published: 2024-03-04 (Crawled : 22:00) - biospace.com/
MSCLF | $0.3895 18.14% 90K
|
n/a
|
| O: 2.24%
H: 0.0%
C: 0.0%
sat-3247 conference positive preclinical
Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy
Published: 2024-02-23 (Crawled : 22:00) - biospace.com/
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: 0.28%
H: 0.0%
C: 0.0%
LEGN | $47.16 -3.42% -3.54% 820K
|
Health Technology
|
| O: 2.07%
H: 5.02%
C: 4.92%
carvykti chmp biotech positive treatment therapy
Streamline Health® Improves Liquidity Position and Appoints New Directors
Published: 2024-02-07 (Crawled : 22:00) - globenewswire.com
STRM | $0.351 -1.71% -1.74% 53K
|
Technology Services
|
| O: 2.94%
H: 22.86%
C: 15.74%
health
Investigational targeted oral peptide JNJ-2113 demonstrated positive results in moderate-to-severe plaque psoriasis in Phase 2b study published in New England Journal of Medicine
Published: 2024-02-07 (Crawled : 22:00) - prnewswire.com
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: -0.63%
H: 0.0%
C: 0.0%
PTGX | $25.23 -1.33% -1.35% 390K
|
Health Technology
|
| O: -0.04%
H: 4.09%
C: 2.8%
jnj-2113 psoriasis positive results study
Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine
Published: 2024-01-31 (Crawled : 22:00) - globenewswire.com
NTLA | $21.3 -0.93% -0.94% 1.1M
|
Health Technology
|
| O: 0.88%
H: 8.11%
C: 5.12%
ntla-2002 positive publication therapeutics
Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap
Published: 2024-01-18 (Crawled : 22:00) - globenewswire.com
AXGN | $6.55 -5.62% -5.95% 240K
|
Health Technology
|
| O: 0.98%
H: 7.06%
C: 6.81%
positive topline trial results
BridgeBio Pharma Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal of Medicine
Published: 2024-01-10 (Crawled : 22:00) - globenewswire.com
BBIO | $24.98 0.0% 2M
|
Health Technology
|
| O: -1.4%
H: 0.08%
C: -0.31%
pharma positive publication results study
APA promotes Stephen J. Riney to position of President and Chief Financial Officer
Published: 2024-01-09 (Crawled : 22:00) - globenewswire.com
APA | $32.43 0.53% 0.52% 5.7M
|
Energy Minerals
|
| O: -0.18%
H: 0.0%
C: -1.03%
financial
Achondroplasia Treatment Drug Market to Register Positive Growth by 2032, Assesses DelveInsight | Key Companies in the Market - Ascendis Pharma, QED Therapeutics (BridgeBio), Novartis, Sanofi, RIBOMIC
Published: 2024-01-09 (Crawled : 22:00) - prnewswire.com
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.13%
H: 0.0%
C: 0.0%
drug companies achondroplasia positive treatment key therapeutics growth market
GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687
Published: 2024-01-04 (Crawled : 22:00) - biospace.com/
GLYC | $2.16 -5.26% -5.56% 880K
|
Health Technology
|
| O: 2.31%
H: 4.84%
C: -3.23%
gmi-1687 positive results study
Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
Published: 2023-12-20 (Crawled : 22:00) - globenewswire.com
ROIV | $10.37 -0.67% -0.68% 3.4M
|
Manufacturing
|
| O: 4.52%
H: 2.02%
C: 1.25%
IMVT 4 | $28.34 -0.32% -0.32% 1.2M
|
Health Technology
|
| O: 11.69%
H: 0.64%
C: -3.24%
disease positive results
Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
Published: 2023-12-20 (Crawled : 22:00) - globenewswire.com
IMVT 4 | $28.34 -0.32% -0.32% 1.2M
|
Health Technology
|
| O: 11.69%
H: 0.64%
C: -3.24%
disease positive results
Vertex Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
Published: 2023-12-15 (Crawled : 22:00) - biospace.com/
VRTX | News | $393.51 0.1% 0.1% 950K
|
Health Technology
|
| O: 0.38%
H: 0.84%
C: 0.62%
first disease chmp positive cell treatment
Metastatic Prostate Cancer Market to Exhibit Positive Growth at a CAGR of 22% and 7.5% for mHSPC and mCRPC, respectively During the Study Period (2019-2032), Assesses DelveInsight
Published: 2023-12-13 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 0.25%
H: 0.0%
C: 0.0%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 1.8%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
positive cancer growth study market
Chronic Inflammatory Demyelinating Polyneuropathy Market to Register Positive Growth During the Study Period (2019-2032), Evaluates DelveInsight | Key Companies to Watch Out - Octapharma, argenx, Immunovant Sciences, Sanofi, Janssen, Takeda
Published: 2023-12-12 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -0.06%
H: 2.36%
C: 2.36%
UCBJY | $64.07 -4.38% 72K
|
Manufacturing
|
| O: -0.62%
H: 1.01%
C: 1.01%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: -0.71%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.27%
H: 2.28%
C: 2.16%
CPRX | $15.35 -4.06% -4.23% 1.4M
|
Health Technology
|
| O: -0.37%
H: 5.49%
C: 5.49%
companies positive growth study market
Genentech’s Kadcyla Is the First Targeted Therapy to Show Significant Overall Survival Benefit in People With HER2-Positive Early-Stage Breast Cancer With Residual Invasive Disease After Neoadjuvant Treatment
Published: 2023-12-08 (Crawled : 22:00) - biospace.com/
IMGN | $31.23 0.03% 49M
|
Health Technology
|
| O: -0.2%
H: 0.0%
C: 0.0%
first disease breast cancer treatment therapy show
SIGMA LITHIUM FEATURED AT COP-28 FOR ITS CLEAN TECHNOLOGY, PIONEERING PRACTICES IN ENVIRONMENTAL SUSTAINABILITY AND POSITIVE SOCIAL IMPACT FOR A FOURTH YEAR
Published: 2023-12-05 (Crawled : 22:00) - sigmalithiumresources.com
SGML | $13.415 -0.63% -0.63% 1.5M
|
Mining, Quarrying, and Oil and ...
|
| O: 1.1%
H: 5.81%
C: 0.04%
LTUM | $0.0379 33.16% 85K
|
Mining, Quarrying, and Oil and ...
|
| O: 10.21%
H: 0.0%
C: -9.26%
cop-28 year lithium positive impact
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.